Overview of Dr. Kantoff
Dr. Philip Kantoff is the CEO and Co-Founder of Convergent Therapeutics in Cambridge, Massachusetts. He is a medical oncologist and former Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is also the Jerome and Nancy Kohlberg Chair Emeritus at Harvard Medical School. He received his medical degree from The Warren Alpert Medical School of Brown University, his residency at NYU-Bellevue in New York and his fellowship in medical oncology at the Dana-Farber Cancer Institute.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1989
NYU Grossman School of MedicineResidency, Internal Medicine, 1979 - 1983
The Warren Alpert Medical School of Brown UniversityClass of 1979
Certifications & Licensure
MA State Medical License 1987 - 2025
NY State Medical License 1979 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- Boston Magazine Castle Connolly, 2008-2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Publications & Presentations
PubMed
- Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.Chen, N., McGrath, C., Ericsson, C., Vaselkiv, J., Rencsok, E., Stopsack, K., Guard, H., Autio, K., Rathkopf, D., Enting, D., Bitting, R., Mateo, J., Githiaka, C., Chi...> ;Cancer Epidemiology, Biomarkers & Prevention. 2024 Mar 1
- Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.Rencsok, E., Slopen, N., McManus, H., Autio, K., Morgans, A., McSwain, L., Barata, P., Cheng, H., Dreicer, R., Gerke, T., Green, R., Heath, E., Howard, L., McKay, R., ...> ;Cancer Research Communications. 2024 Jan 8
- Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.Van Neste, L., Henao, R., Wojno, K., Signes, J., DeHart, J., Busta, A., Marriott, E., Willing, M., Argentini, A., Hurley, P., Korman, H., Hafron, J., Putzi, M., Pieczo...> ;The Journal of Urology. 2024 Mar 1
- Join now to see all
Journal Articles
- Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with SurvivalMark M Pomerantz, Philip W Kantoff, The Prostate
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Lectures
- 16th Biennial Urologic Cancer CourseHarvard Medical School, Boston, Massachusetts - 10/11/2012
Other
- Immunotherapy for castration resistant prostate cancerKantoff PW
http://www.uptodate.com/contents/immunotherapy-for-castration-resistant-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-01-03 - Malignancies of the renal pelvis and ureterKantoff PW, Richie JP
http://www.uptodate.com/contents/malignancies-of-the-renal-pelvis-and-ureter
UpToDate, Wolters Kluwer Health - 2012-09-24 - Extragonadal germ cell tumors involving the mediastinum and retroperitoneumKantoff PW, Gilligan TD
http://www.uptodate.com/contents/extragonadal-germ-cell-tumors-involving-the-mediastinum-and-retrope
UpToDate, Wolters Kluwer Health - 2012-02-27 - Join now to see all
Authored Content
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018
Press Mentions
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022- POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-Α (Rosopatamab-225Ac) in Combination with PNT2002 for Progressive mCRPCSeptember 14th, 2021
- Ziopharm Finds New CEO After Six-Month Search; CFO Transition at Lonza to Take Place in DecemberSeptember 3rd, 2021
- Join now to see all
Grant Support
- Df/Hcc Spore In Prostate CancerNational Cancer Institute2007–2011
- Developmental Research ProgramNational Cancer Institute2007–2011
- Career Development ProgramNational Cancer Institute2007–2011
- Administration, Evaluation, And Planning CoreNational Cancer Institute2007–2011
- Molecular Signatures Of Lethal An Indolent Prostate CancerNational Cancer Institute2007–2009
- Spore In Prostate CancerNational Cancer Institute2002–2006
- Developmental Projects ProgramNational Cancer Institute2002
Professional Memberships
- Member
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Massachusetts Blue Care Elect PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPOHarvard Pilgrim HMO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Tufts Health Plan PPO
UniCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
